The sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin was recently shown to decrease the incidence of cardiac mortality or hospitalization for heart disease in individuals with cardiac failure and a decreased ventricular component in the EMPEROR-Reduced study. In individuals with cardiac failure and a maintained ventricular component (HFpEF) even without diabetes, empagliflozin reduces the risk of…
The ENVISAGE-TAVI AF study is the biggest to evaluate an edoxaban-based approach to anticoagulation, which really is presently the mainstay of therapy, in this client group. It proves that edoxaban isn’t worse than anticoagulation. The findings, which potentially lead to a new therapeutic approach, are presented as a late-breaking medical trial at the European Society…
Although hypertension is the globe’s top cause of death, inadequate hypertension regulation is nevertheless frequent. When contrasted to the conventional practice of mono, in which therapy begins with just one medication, a novel technique in which individuals are begun on a tablet comprising 4 drugs, at a fourth of their regular dosage has indeed been…
Henrike Heyne, MD (now at the Hasso Plattner Institute) and coworkers at the Research center for Molecular Medicine (FIMM) at the University of Helsinki, Finland, extracted data on 9660 people with epilepsy-related diagnoses and treatment from the over 269K persons would include in FinnGen venture and likened their polygenic threat ratings to that of control…
Link Placeholder